20/20 BioLabs Unveils IBM-Powered OneTest for Diabetes, Dementia and Cardiovascular Risk
20/20 BioLabs launched OneTest for Longevity, using IBM watsonx.ai to assess chronic disease risk via inflammatory biomarkers and dietary inputs, now available commercially. The AI solution calculates diabetes, dementia and cardiovascular risk by analyzing thousands of studies in the company’s CLIA-licensed, CAP-accredited lab in Gaithersburg, MD.
1. Product Launch and Commercial Availability
On February 25, 2026, 20/20 BioLabs introduced OneTest for Longevity as a commercially available blood test solution. The launch marks its first AI-driven product release since listing on Nasdaq.
2. AI Integration and Data Analysis
The platform leverages IBM watsonx.ai along with open-source Docling and Granite 4.0 foundation models to integrate inflammatory biomarker data, dietary and lifestyle inputs, and analyze thousands of peer-reviewed studies for explainable health outputs.
3. Test Capabilities and Laboratory Operations
OneTest calculates individual risk for diabetes, dementia and cardiovascular disease and delivers personalized dietary recommendations. All testing is conducted in the company’s CLIA-licensed, CAP-accredited laboratory in Gaithersburg, Maryland.
4. Market Position and Potential Impact
The solution was developed in partnership with DAISource and follows the company’s February 19 Nasdaq debut. This offering could generate early revenue and strengthen its AI-powered diagnostics portfolio.